New combination actinic keratosis treatment

on the 29 July 2011

In the UK, actinic keratosis affects approximately one in four people aged 60 years and over | SCIENCE PHOTO LIBRARY

Actikerall is a combination of salicylic acid (10%) and fluorouracil (0.5%) indicated for the treatment of actinic keratosis. The cutaneous solution is licensed for use on slightly palpable and/or moderately thick hyperkeratotic lesions (grade I/II) in immunocompetent patients. Salicylic acid is a keratolytic agent and fluorouracil inhibits the keratinocyte proliferation seen in actinic keratosis.

The efficacy of the salicylic acid/fluorouracil combination was established in a 12-week Phase III trial that enrolled 470 patients with 4–10 lesions. In the per protocol analysis, 72.0% of patients achieved complete histological clearance of a representative lesion after 12 weeks, compared with 59.1% of those treated with diclofenac gel and 44.8% of those who received placebo.

Actikerall is supplied in a 25ml bottle, sufficient for a course of treatment. It is applied once daily using the integral brush.

View Actikerall drug record

Further Information: Almirall